2025年A股市场显著走强，上证指数更是刷新近十年新高。随着股市的持续上涨，权益类基金受益匪 浅。中基协的最新数据显示，截至今年7月末，公募基金管理规模首次突破35万亿元大关。 纵观上半年公募基金公司业绩表现，净利润规模在2亿元以上的基金公司共有19家，其中，净利润增速 超过40%的仅有广发基金、中欧基金、兴业基金。 在今年股市上涨行情中，一批出色的基金经理为市场提供了"多元适配" 的投资解法，偏好短期收益的 投资者可追随科技、医药赛道的产业红利，追求稳健的投资者能依托价值策略把握低估机遇，擅长周期 布局的投资者也能找到资源品领域的轮动机会。 对科技股的精准操作，使上述几位基金经理在管产品的业绩大幅上涨。 值得一提的是，中欧基金的冯炉丹在管的中欧数字经济混合成立至今还不足两年时间，凭借对科技股的 精准把握，目前的任职回报已达到175.71%。 其中，汇添富的马翔、张韡，中欧的蓝小康、冯炉丹，易方达的祁禾、嘉实的王贵重、大成的韩创等在 今年均表现不俗，在 2025 年结构性行情中展现出强大投研实力。 今年8月，算力板块强势发力，科创50指数大涨推动沪指站上 3800 点。截至9月2日，马翔管理的汇添富 科技创新 ...

AI基金汇添富价值成长均衡投资混合A（011271）披露2025年中期报告，上半年基金利润1.13亿元，加权平均基金份额本期利润0.055元。报告期内，基金净 值增长率为10.53%，截至上半年末，基金规模为11.49亿元。 该基金属于偏股混合型基金。截至9月2日，单位净值为0.668元。基金经理是谢昌旭，目前管理的5只基金近一年均为正收益。其中，截至9月2日，汇添富高 质量成长精选2年持有混合近一年复权单位净值增长率最高，达41.37%；汇添富稳健添盈一年持有混合最低，为11.61%。 基金管理人在中期报告中表示，报告期内，本基金基于对行业趋势的判断，减持了部分受需求减弱和竞争加剧影响的个股，同时增持了成长性突出的优质科 技、创新药及新兴消费品公司。市场方面上半年增加了港股中优质公司的比重，主要集中于新兴消费品和创新药等领域。 截至9月2日，汇添富价值成长均衡投资混合A近三个月复权单位净值增长率为19.81%，位于同类可比基金92/182；近半年复权单位净值增长率为18.53%，位 于同类可比基金90/182；近一年复权单位净值增长率为41.01%，位于同类可比基金103/181；近三年复权单位净值增长率为 ...

AI基金财通资管数字经济混合发起式A（017483）披露2025年中期报告，上半年基金利润9207.94万元，加权平均基金份额本期利润0.243元。报告期内，基 金净值增长率为29.5%，截至上半年末，基金规模为6.49亿元。 该基金属于偏股混合型基金，长期投资于TMT股票。截至9月2日，单位净值为1.824元。基金经理是包斅文，目前管理的3只基金近一年均为正收益。其中， 截至9月2日，财通资管数字经济混合发起式A近一年复权单位净值增长率最高，达141.68%；财通资管创新成长混合A最低，为87.28%。 基金管理人在中期报告中表示，展望下半年，我们认为宏观经济的增长压力依旧存在，中国经济正处于新旧动能的转换关键期，新质生产力、未来产业依然 是我们投资的重点。总体看在宏观经济压力较大时市场流动性依然会比较宽松。我们认为总体对权益市场较为友好，作为管理人应当积极把握其中结构性的 机会。另外我们也会积极关注经济刺激政策超预期带来的风格切换的行情，也积极做好相应投资预案。 截至9月2日，财通资管数字经济混合发起式A近三个月复权单位净值增长率为50.21%，位于同类可比基金96/328；近半年复权单位净值增长率为43 ...

中国经济网北京9月3日讯今日，中海基金公告，中海医药混合增聘姚炜，梁静静离任。 姚炜历任凯基证券(原台证证券)上海代表处分析师、光大证券国际有限公司分析师、交银国际(上海)股 权投资管理有限公司分析师、兴业证券股份有限公司高级分析师。2017年10月进入中海基金，曾任高级 分析师兼基金经理助理，现任基金经理。 中海医药混合A/C成立于2014年12月17日，截至2025年9月2日，其今年来收益率为33.55%、32.73%，成 立来收益率为142.15%、121.29%，累计净值为2.4740元、2.3100元。 | 基金名称 | 中海医药健康产业精选灵活配置混合型证券投资基金 | | --- | --- | | 基金简称 | 中海医药混合 | | 基金主代码 | 000878 | | 基金管理人名称 | 中海基金管理有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》 | | 基金经理变更类型 | 增聘基金经理、解聘基金经理 | | 新任基金经理姓名 | 姚炜 | | 共同管理本基金的其他经 | | | 理姓名 | | | 离任基金经理姓名 | 梁静静 | ...

Group 1 - Zhongke Chuangda's stock increased by 5.1%, reaching 78.17 CNY per share, with a trading volume of 750 million CNY and a turnover rate of 2.65%, resulting in a total market capitalization of 35.959 billion CNY [1] - Zhongke Chuangda, established on March 7, 2008, and listed on December 10, 2015, is a leading global provider of intelligent operating systems and edge intelligent products and technologies [1] - The company's revenue composition includes software development (37.17%), technical services (31.38%), product sales and others (29.20%), and software licensing (2.24%) [1] Group 2 - Huazhong Fund's Huazhong Chuangye 50 ETF (159949) reduced its holdings by 221,400 shares in the second quarter, now holding 3.3233 million shares, which accounts for 0.9% of the circulating shares [2] - The estimated floating profit from this transaction is approximately 12.5954 million CNY [2] - The Huazhong Chuangye 50 ETF was established on June 30, 2016, with a current scale of 25.16 billion CNY and a year-to-date return of 39.29%, ranking 651 out of 4222 in its category [2]

上市公司半年报披露收官，险资私募基金持股曝光。 鸿鹄基金一期规模500亿元，2024年3月开始投资，至今年3月投资已悉数落地。新华资产总裁陈一江近 日表示，截至二季度末，鸿鹄基金二期基本完成建仓工作；三期从7月初开始启动，进展顺利。今年上 半年，试点基金的风险指标低于基准，收益指标高于基准，实现了功能性与盈利性双丰收，试点基金业 绩有信心保持长期韧性。截至目前，保险资金长期投资改革试点已有三批，试点金额合计2220亿元。前 两批试点机构均已获批成立私募基金公司。 成立最早、规模最大的鸿鹄基金已跻身至少6家上市公司前十大股东名单。其中，鸿鹄基金二期二季度 末现身于中国石油、中国神华前十大股东，鸿鹄基金三期1号位列中国石化前十大股东。鸿鹄基金一期 跻身伊利股份、陕西煤业、中国电信的前十大股东。 据记者了解，险资长期投资改革试点基金通过优化会计处理，可以有效降低权益工具投资的收益波动， 优化资产负债管理。有助于保险公司提升权益投资并实现长期投资，发挥保险资金的市场稳定器作用； 有利于资本市场平稳运行，实现保险资金与资本市场的良性互动、共同发展。 鸿鹄基金是保险资金长期投资改革试点基金，已设立一期、二期、三期1号和三 ...

Group 1: Mona Lisa (002918) - The company's revenue from distribution channels decreased by 10% year-on-year in the first half of 2025, while the engineering channel saw a decline of 42.68% [1] - The distribution channel accounted for 82.98% of revenue in Q2, with ongoing declines in engineering [1] - The company is facing intense industry competition with no positive price changes, and is focusing on cost reduction and efficiency improvements [1] - The strategic customer business proportion has dropped to 17%, with 83% of demand coming from non-real estate sectors [1] - The company maintains a "large tiles, large building materials, large home" strategy, with low financial investment proportion [1] Group 2: Mountain Outside Mountain - The domestic market for blood purification equipment generated revenue of 152 million yuan, a year-on-year increase of 14.60% [2] - Blood purification consumables revenue reached 85.34 million yuan, up 46.17%, with self-produced consumables growing by 91.90% [2] - R&D investment increased by 37.12% to 36.51 million yuan, while sales expenses rose by 26.64% to 62.80 million yuan [2] - The overseas market revenue was 86.82 million yuan, reflecting a growth of 41.30%, with significant increases in North America and Africa [2] - The company is a drafting unit for national standards and is enhancing its international competitiveness through core technology [2] Group 3: Leyard (300296) - The smart display segment experienced a 20% quarter-on-quarter growth, driven by high demand in overseas markets, particularly North America [3] - Business growth is supported by demand from cinemas, virtual shooting, and large events [3] - The company is optimizing production capacity across its factories in Slovakia, Shenzhen, and Wuxi to mitigate tariff impacts [3] - The AR glasses are expected to launch in October, targeting B-end customers [3] - The AI and spatial computing segments saw a year-on-year decline due to price reductions and increased R&D investment [3]

Group 1: Dekoli - The company is experiencing rapid growth in computing power demand, but faces challenges with insufficient production capacity and supply chain resources, leading to order delivery issues [1] - Revenue from data communication products is increasing, with access and data products accounting for nearly 40% of total revenue; however, telecom business revenue has decreased by approximately 8% year-on-year [1] - A new factory is expected to be operational in the second half of the year, which is anticipated to improve the situation; OCS products have received orders worth millions [1] - The company's factory in Thailand is projected to start production after the 2026 Spring Festival, with some clients already certified [1] - The company emphasizes enhancing core competitiveness to address uncertainties in tariff policies [1] Group 2: Xinmai Medical - The company reported a revenue of 714 million yuan and a net profit of 315 million yuan during the reporting period, with a proposed cash dividend of 1.3 yuan per share, totaling 157 million yuan [1] - The Cratos product was launched domestically in March, with a listing price below 100,000 yuan, and its promotion is exceeding expectations; Hector has received custom certification in the EU and has completed clinical implants in multiple countries [1] - Research and development investment is expected to be around 10% this year, maintaining a range of 10%-15% in the future [1] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total revenue, primarily due to the consolidation of Lombard and organic growth, with plans to expand coverage from 45 to 60 countries next year [1] - High-margin products such as Talos, Cratos, and Fontus are set to be launched internationally [1] Group 3: Green Fund - Green Fund was established in 2016, with total assets under management of 25.643 billion yuan, ranking 110 out of 210 in public funds [2] - The fund has 61 public funds under management, ranking 91 out of 210, and employs 12 fund managers, ranking 97 out of 210 [2] - The best-performing public fund product in the past year is the Green High Dividend Preferred Mixed A, with a latest net value of 1.84 and a growth of 118.24% over the past year [2] - The latest public fund product launched is the Green Technology Growth Mixed A, which is equity-oriented and has a subscription period from August 8, 2025, to November 7, 2025 [2]

Core Insights - The article discusses the recent disclosures of half-year reports from listed companies, highlighting the investments made by the Honghu Fund, which is the largest and earliest established private equity fund backed by insurance capital in China [1][2]. Group 1: Honghu Fund Investments - Honghu Fund has become a top ten shareholder in at least six listed companies, including China Petroleum, China Shenhua, and China Petrochemical [1]. - The investment criteria for Honghu Fund include companies with good governance, stable operations, relatively stable dividends, good liquidity, and strong returns, focusing on large-cap blue-chip companies [1]. - The companies in which Honghu Fund has invested exhibit characteristics of high dividend yields and large market capitalizations, with dividend yields exceeding 5% for companies like Shaanxi Coal and China Shenhua [1]. Group 2: Fund Performance and Strategy - As of the end of the second quarter, the second phase of the Honghu Fund has nearly completed its investment allocation, while the third phase commenced in early July and is progressing smoothly [2]. - The pilot fund has achieved lower risk indicators and higher return indicators compared to benchmarks, indicating a successful balance between functionality and profitability [2]. - The pilot fund's total amount has reached 222 billion yuan, with the first two batches of pilot institutions approved to establish private equity fund companies [2].

前海开源基金管理有限公司 2025年9月3日 根据《中国证券监督管理委员会关于证券投资基金估值业务的指导意见》（证监会公告[2017]13号）以 及中国证券投资基金业协会《关于发布中基协（AMAC）基金行业股票估值指数的通知》(中基协发 [2013]第13号)等有关规定，经前海开源基金管理有限公司（以下简称"本公司"）与基金托管人协商一 致，自2025年9月2日起，以中基协AMAC行业指数为计算依据，对本公司旗下基金（ETF除外）所持有 的"芯原股份"（证券代码：688521），采用基金估值工作小组《关于停牌股票估值的参考方法》中 的"指数收益法"进行估值。 自 "芯原股份"复牌且其交易体现了活跃市场交易特征后，恢复采用交易所当日收盘价进行估值，届时 不再另行公告。敬请投资者予以关注。 特此公告。 ...